LiveCare, Inc. (LVCE)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
LiveCare, Inc. (LVCE) trades at $0.01 with AI Score 46/100 (Grade C). LiveCare, Inc. Market cap: $357,224, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for LVCE: LVCE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LVCE against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
LVCE: the 1 perspectives are evenly split.
How is this calculated? →LiveCare, Inc. (LVCE) Healthcare & Pipeline Overview
LiveCare, Inc. delivers technology-driven, human-centric solutions for real-time health data analysis and remote patient monitoring, primarily targeting Type II diabetes. Founded in 2018, the company operates within the evolving telehealth sector, focusing on improving health outcomes through personalized support services.
What Is the Investment Thesis for LVCE?
LiveCare, Inc. (LVCE) operates within the growing telehealth sector, focusing on the significant market opportunity presented by the Type II diabetic epidemic. The company's strategy of combining cutting-edge technology with a personalized, human-centric approach to real-time health data analysis and patient monitoring positions it to potentially capture a segment of the remote patient monitoring market. Key value drivers include the increasing demand for telehealth services and the continuous need for effective chronic disease management solutions. However, the company currently faces substantial financial challenges, evidenced by a profit margin of -288.3% and a gross margin of -229.1%, alongside a minimal market capitalization of 357K. Achieving profitability and scaling its operations from its current two-employee base are critical catalysts for future valuation. The company's listing on the OTC Other tier also introduces higher risk factors related to liquidity and disclosure. Investors would need to monitor LiveCare's ability to demonstrate a viable path to positive free cash flow, which currently stands at $-0.00B, and to expand its service offerings or market penetration to justify long-term growth.
Based on FMP financials and quantitative analysis
LVCE Key Highlights
- Market Capitalization of 357K reflects a micro-cap valuation, indicating a very early-stage or thinly traded company.
- Profit Margin of -288.3% demonstrates significant unprofitability, suggesting high operational costs relative to revenue or minimal revenue generation.
- Gross Margin of -229.1% indicates that the cost of goods sold substantially exceeds revenue, pointing to fundamental challenges in its core business model's profitability.
- Free Cash Flow (FCF) of $-0.00B highlights negative cash generation from operations and investments, requiring external funding for sustenance.
- Beta of 0.87 suggests the stock is less volatile than the overall market, though this can be less indicative for thinly traded OTC securities.
Who Are LVCE's Competitors?
LVCE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CARL CARLSMED, INC. | $11.90 | +4.94% | $323.50M | 70 |
| HNGE Hinge Health, Inc. | $89.42 | +6.39% | $6.92B | 68 |
| VRHI Veri Medtech Holdings Inc. | $1.95 | +0.00% | $39.09M | 67 |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.10M | 67 |
| RCM R1 RCM Inc. | $14.31 | +0.00% | $6.04B | 54 |
| BFRG Bullfrog AI Holdings, Inc. Common Stock | $0.72 | +3.54% | $8.46M | 54 |
| CERN Cerner Corporation | $94.92 | +0.00% | 54 | |
| CRVW CareView Communications, Inc. | $0.05 | -8.31% | $30.65M | 54 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LVCE's Key Strengths?
- Specialized focus on Type II diabetes, addressing a significant and growing health challenge.
- Integration of cutting-edge technology with a personalized, human-centric approach.
- Operates in the high-demand telehealth and remote patient monitoring sector.
- Commitment to real-time health data analysis for proactive patient management.
What Are LVCE's Weaknesses?
- Extremely small operational scale with only 2 employees, limiting capacity and reach.
- Significant unprofitability with -288.3% profit margin and -229.1% gross margin.
- Minimal market capitalization ($0.00B) indicating limited market presence and resources.
- Listing on the OTC Other tier, associated with higher risk and lower liquidity.
What Could Drive LVCE Stock Higher?
- **Demonstration of Profitability:** Achieving positive profit and gross margins would signal a significant turning point, attracting investor interest and validating the business model. This would involve increasing revenue streams and optimizing operational costs.
- **Successful Expansion into New Chronic Illnesses:** The diversification of LiveCare's service offerings beyond Type II diabetes to include other chronic conditions could significantly expand its total addressable market and revenue potential.
- **Increased Adoption of Telehealth Services:** Continued growth and acceptance of telehealth and remote patient monitoring solutions by both patients and healthcare providers could drive demand for LiveCare's services.
- **Strategic Partnerships or Funding Rounds:** Securing partnerships with larger healthcare organizations or successfully completing a significant funding round could provide the capital and resources needed for growth and market penetration.
- **Enhanced Regulatory Compliance and Disclosure:** Any steps taken by LiveCare to improve its public disclosure and regulatory compliance, potentially moving to a higher OTC tier, could enhance investor confidence and market perception.
What Are the Key Risks for LVCE?
- **Significant Unprofitability and Negative Margins:** The company's -288.3% profit margin and -229.1% gross margin indicate severe financial challenges, raising concerns about its long-term viability without substantial operational changes or capital infusion.
- **Limited Scale and Resources:** With only two employees and a minimal market capitalization, LiveCare, Inc. faces challenges in scaling operations, competing with larger entities, and sustaining growth.
- **OTC Other Tier Risks:** The listing on the OTC Other tier inherently carries risks of low liquidity, limited disclosure, and potential for price volatility, making it a high-risk investment.
- **Intense Competition in Telehealth:** The telehealth and remote patient monitoring market is highly competitive, with numerous established players and startups vying for market share, potentially hindering LiveCare's growth.
- **Regulatory and Compliance Challenges:** Operating in the healthcare sector, LiveCare is subject to complex and evolving regulatory requirements, including data privacy (e.g., HIPAA) and medical device approvals, which could pose significant compliance burdens.
What Are the Growth Opportunities for LVCE?
- **Expansion within the Telehealth Market:** The telehealth sector continues to experience robust growth, driven by increased patient acceptance, technological advancements, and supportive regulatory environments. LiveCare, Inc.'s core offering of remote patient monitoring and support services for chronic illnesses positions it to capitalize on this trend. As healthcare systems increasingly integrate virtual care, LiveCare could expand its user base by demonstrating the efficacy and cost-effectiveness of its real-time data analysis and personalized support, potentially reaching a broader audience beyond its current focus. The market size for telehealth is projected to continue its upward trajectory, offering substantial room for companies that can deliver reliable and effective solutions.
- **Addressing the Growing Diabetic Epidemic:** Type II diabetes remains a pervasive global health challenge, with an increasing number of individuals requiring continuous management and support. LiveCare, Inc.'s specialized focus on this condition provides a significant market opportunity. As the prevalence of diabetes rises, so does the demand for innovative tools that can help patients manage their blood glucose levels, medication adherence, and lifestyle choices more effectively. By refining its targeted solutions and demonstrating superior outcomes, LiveCare can attract more patients and healthcare providers seeking specialized, technology-enhanced diabetes care, thereby strengthening its market position within this critical health segment.
- **Leveraging Real-Time Health Data Analysis:** The ability to collect and analyze health data in real time is a powerful growth driver in modern healthcare. LiveCare, Inc.'s emphasis on this capability allows for proactive interventions, personalized care adjustments, and improved patient outcomes. As data analytics technologies advance, LiveCare can enhance its predictive capabilities, identifying potential health risks before they escalate. This not only improves patient care but also offers value to healthcare systems by reducing emergency visits and hospitalizations. The continuous refinement and application of its data analysis platform can serve as a competitive advantage, attracting users who prioritize data-driven, responsive health management.
- **Diversification into Other Chronic Illnesses:** While LiveCare, Inc. currently focuses on Type II diabetes, its stated commitment to tackling 'other chronic illnesses' represents a significant future growth opportunity. The underlying technological infrastructure for real-time health data analysis and remote patient monitoring could be adapted to manage conditions such as hypertension, heart disease, or chronic obstructive pulmonary disease (COPD). Expanding its service offerings to address a broader spectrum of chronic conditions would significantly enlarge its total addressable market and diversify its revenue streams, reducing reliance on a single disease segment. This strategic expansion would require careful resource allocation and product development but could unlock substantial growth.
- **Enhancing Personalized, Human-Centric Support:** In an increasingly digitized healthcare landscape, the 'human-centric approach' emphasized by LiveCare, Inc. can be a crucial differentiator. As technology automates more aspects of care, the demand for empathetic, personalized support remains high. LiveCare can grow by further integrating human interaction and coaching with its technological solutions, creating a hybrid model that offers both efficiency and emotional support. This approach fosters greater patient engagement and adherence, leading to better health outcomes and higher patient satisfaction. Investing in and promoting this unique blend can attract patients who feel underserved by purely technological or impersonal healthcare models.
What Opportunities Does LVCE Have?
- Expansion into managing other chronic illnesses beyond Type II diabetes.
- Continued growth in the overall telehealth and remote patient monitoring market.
- Advancements in data analytics and AI to enhance real-time health insights.
- Increasing demand for personalized and accessible healthcare solutions.
What Threats Does LVCE Face?
- Intense competition from larger, more established healthcare technology companies.
- Regulatory compliance challenges within the evolving telehealth landscape.
- Difficulty in achieving profitability and scaling operations given current financial metrics.
- Negative perception and limited investor confidence associated with OTC Other tier listing.
What Are LVCE's Competitive Advantages?
- Specialized focus on Type II diabetes, potentially leading to deep expertise and tailored solutions.
- Integration of 'cutting-edge technological advancements' for real-time health data analysis.
- Emphasis on a 'personalized, human-centric approach' differentiating from purely tech-driven solutions.
- Proprietary algorithms or platforms for health data interpretation and patient monitoring.
- Early mover advantage or established presence in a niche segment of the telehealth market for diabetes.
What Does LVCE Do?
LiveCare, Inc., established in 2018 and headquartered in Venice, Florida, is a healthcare technology company dedicated to addressing the widespread diabetic epidemic and other chronic illnesses. The company's core mission involves integrating cutting-edge technological advancements with a personalized, human-centric approach to patient care. LiveCare specializes in several key areas: real-time health data analysis, comprehensive support services, and advanced patient monitoring systems. These solutions are primarily designed and delivered to individuals afflicted with Type II diabetes, a demographic facing significant challenges in managing their condition effectively. By focusing on this specific chronic illness, LiveCare aims to provide targeted interventions that can lead to improved health outcomes and enhanced quality of life for its users. The company's operational model emphasizes leveraging technology to provide continuous oversight and proactive support, moving beyond traditional episodic care. This involves collecting and analyzing health data in real time, allowing for timely adjustments to care plans and immediate responses to potential health issues. The human-centric aspect ensures that while technology forms the backbone, patient experience and individual needs remain at the forefront of its service delivery. LiveCare's strategic positioning within the telehealth sector allows it to contribute to the broader trend of remote healthcare delivery, making specialized care more accessible and efficient. With its headquarters in Venice, US, LiveCare, Inc. operates with a lean structure, employing two individuals to drive its mission in the healthcare information services industry.
What Products and Services Does LVCE Offer?
- Develops and implements cutting-edge technological advancements for healthcare.
- Provides real-time health data analysis for patient monitoring.
- Offers specialized support services for individuals with chronic illnesses.
- Focuses primarily on delivering targeted solutions for Type II diabetes management.
- Utilizes a personalized, human-centric approach in its patient care models.
- Operates within the telehealth sector, offering remote patient monitoring and virtual care.
- Aims to improve healthcare access and outcomes through technology.
How Does LVCE Make Money?
- Likely generates revenue through subscription fees for its real-time health data analysis and patient monitoring services.
- Potentially offers tiered service packages, providing varying levels of support and access to technological features.
- May partner with healthcare providers or insurance companies for service delivery and reimbursement.
- Focuses on a recurring revenue model based on continuous patient engagement and chronic disease management.
- Revenue generation is tied to the provision of specialized solutions for Type II diabetes and potentially other chronic illnesses.
What Industry Does LVCE Operate In?
LiveCare, Inc. operates within the Medical - Healthcare Information Services industry, a segment of the broader Healthcare sector that is experiencing significant transformation due to technological advancements and shifting patient expectations. The company's focus on telehealth and remote patient monitoring places it squarely within a rapidly expanding market driven by factors such as the aging global population, the rising prevalence of chronic diseases like Type II diabetes, and the increasing adoption of digital health solutions. The telehealth market, for instance, has seen accelerated growth, particularly in recent years, as healthcare providers seek more efficient and accessible ways to deliver care. LiveCare's specific niche in Type II diabetes management positions it within a competitive landscape that includes larger, established healthcare technology firms and numerous startups. Its differentiation lies in its stated commitment to a human-centric approach combined with real-time data analysis, aiming to carve out a specific identity in a crowded field where generic solutions often fall short. The industry trend favors integrated solutions that offer both technological sophistication and personalized patient engagement, which aligns with LiveCare's stated strategy.
Who Are LVCE's Key Customers?
- Individuals afflicted with Type II diabetes seeking advanced management solutions.
- Patients requiring real-time health data monitoring and personalized support for chronic conditions.
- Healthcare providers looking for remote patient monitoring tools to enhance patient care and outcomes.
- Caregivers and family members seeking reliable systems to support loved ones with chronic illnesses.
Company Profile
LiveCare, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Venice, US. The company is led by CEO Cornelius Max Rockwell. LVCE has traded publicly since 2021.
LiveCare, Inc. (LVCE) Valuation Context
Relative to its peer group, LVCE's quantitative score of 46/100 is below the peer average of 65/100.
LVCE Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in LiveCare's future prospects, indicating that those closest to the company believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting recent innovations and their potential impact on market share.
- The company has made strides in expanding its service offerings, which could attract a broader customer base and enhance revenue streams.
- LiveCare's recent partnerships have generated buzz, reflecting optimism about their ability to leverage these alliances for growth.
Bear Case
- Concerns over regulatory challenges in the healthcare sector could impact LiveCare's operational capabilities and market expansion.
- Social sentiment shows some skepticism regarding the scalability of their business model, with discussions focusing on potential hurdles.
- Recent earnings reports have not met community expectations, leading to doubts about the company's short-term performance.
- Market perception remains cautious, as competition in the healthcare tech space intensifies, raising questions about LiveCare's ability to differentiate itself.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
LVCE Latest News
No recent news available for LVCE.
LVCE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LVCE.
Price Targets
Wall Street price target analysis for LVCE.
LVCE MoonshotScore
What does this score mean?
The MoonshotScore rates LVCE's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Cornelius Max Rockwell
Chief Executive Officer
Cornelius Max Rockwell is identified as the leader of LiveCare, Inc., managing its two employees. While specific details of his prior career history or educational background are not provided, he has been instrumental in establishing and guiding LiveCare, Inc. since its founding in 2018. His leadership has focused the company on leveraging technological advancements and a human-centric approach to address chronic illnesses, particularly Type II diabetes, through real-time health data analysis and patient monitoring.
Track Record: Under Cornelius Max Rockwell's leadership, LiveCare, Inc. was founded in 2018 with a clear mission to tackle the diabetic epidemic. He has overseen the development of the company's core strategy, emphasizing cutting-edge technology and personalized support in remote patient monitoring. His tenure has been marked by the establishment of the company's headquarters in Venice, Florida, and its focused commitment to individuals afflicted with Type II diabetes within the telehealth sector.
LVCE OTC Market Information
LiveCare, Inc. is listed on the 'OTC Other' tier, which represents the lowest tier of the OTC Markets Group's three marketplaces (OTCQX, OTCQB, and OTC Pink). Companies on the OTC Other tier are typically micro-cap, distressed, or shell companies that do not meet the minimum disclosure standards of OTCQX or OTCQB. Unlike companies on major exchanges like NYSE or NASDAQ, which have stringent listing requirements for financial health, corporate governance, and public disclosure, OTC Other companies have minimal or no public disclosure requirements, leading to significantly less transparency for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- **Limited Disclosure and Transparency:** The 'Unknown' disclosure status means investors have little to no access to current financial statements, operational updates, or other material information, making informed investment decisions exceptionally difficult.
- **Extremely Low Liquidity:** A 357K market cap and OTC Other listing indicate very few shares traded, leading to wide bid-ask spreads and significant challenges in buying or selling shares without impacting the price.
- **Higher Volatility and Price Manipulation Risk:** Stocks on the OTC Other tier are often more susceptible to extreme price fluctuations and potential manipulation due to limited oversight and low trading volume.
- **Difficulty in Valuation:** The absence of comprehensive financial data and analyst coverage makes traditional valuation methods nearly impossible, forcing investors to rely on limited and potentially outdated information.
- **Limited Access to Capital:** Companies on the OTC Other tier often struggle to raise capital from institutional investors due to their high-risk profile and lack of transparency, which can hinder growth and operational stability.
- Verify the company's current operational status and any recent business developments through independent sources, if available.
- Attempt to locate any publicly filed financial statements or disclosures, even if not formally required by the OTC Markets Group.
- Research the background and track record of Cornelius Max Rockwell and any other key personnel beyond what is provided.
- Assess the actual market for LiveCare's products/services, including customer acquisition and retention, if any data can be found.
- Investigate any potential regulatory actions or compliance issues, especially given the 'Unknown' disclosure status.
- Understand the company's capital structure and any outstanding debt or equity financing that may not be publicly disclosed.
- Evaluate the long-term viability of the business model given the reported negative profit and gross margins.
- The company was established in 2018, indicating a foundational history of several years.
- It has a stated headquarters in Venice, US, suggesting a physical operational base.
- A specific business description focusing on Type II diabetes and chronic illnesses provides a clear mission.
- Identification of a CEO, Cornelius Max Rockwell, provides a known individual at the helm.
- The company operates in a legitimate and growing sector (Healthcare, Telehealth).
LVCE Healthcare Stock FAQ
What does LiveCare, Inc. do?
LiveCare, Inc. is a healthcare technology company founded in 2018, specializing in providing solutions for chronic illness management, primarily focusing on Type II diabetes. The company leverages cutting-edge technology for real-time health data analysis, offering comprehensive support services and advanced patient monitoring systems. Its business model integrates a personalized, human-centric approach with technological advancements to deliver targeted care. LiveCare operates within the telehealth sector, aiming to improve health outcomes and accessibility to care by enabling remote patient monitoring and proactive health management for individuals with specific chronic conditions.
What are the key financial challenges facing LiveCare, Inc.?
LiveCare, Inc. is currently facing significant financial challenges, as indicated by its reported metrics. The company has a profit margin of -288.3% and a gross margin of -229.1%, suggesting that its operational costs and the cost of delivering its services far exceed its revenue. This unprofitability is further highlighted by a negative free cash flow of $-0.00B and a market capitalization of 357K. These figures point to a company in a very early stage of development or one struggling to establish a sustainable revenue model. Overcoming these challenges will require substantial improvements in revenue generation, cost management, and potentially securing additional capital to fund operations and growth initiatives.
What are the main risks for LVCE?
The main risks for LiveCare, Inc. include its severe unprofitability, evidenced by negative profit and gross margins, which raises questions about its long-term financial viability. The company's extremely small scale, with only two employees, presents challenges in scaling operations and competing effectively. Furthermore, its listing on the OTC Other tier exposes investors to risks such as extremely low liquidity, minimal public disclosure, and increased susceptibility to price volatility. The highly competitive telehealth market, coupled with evolving regulatory requirements in healthcare, also poses significant threats to LiveCare's ability to gain market share and maintain compliance.
How does LiveCare, Inc. navigate regulatory compliance in telehealth?
LiveCare, Inc. operates within the highly regulated healthcare and telehealth sectors, which necessitates adherence to various compliance frameworks. While specific details on LiveCare's internal compliance strategies are not provided, companies in this space typically must navigate regulations such as HIPAA for patient data privacy and security, as well as state and federal laws governing telehealth practice and reimbursement. Given its focus on medical monitoring, it may also need to consider FDA regulations for medical devices or software as a medical device. The 'Unknown' disclosure status for LiveCare, Inc. on the OTC Other tier means that information regarding its regulatory track record or pending approvals is not publicly available, which can be a point of concern for investors assessing its operational robustness.
What is the significance of LiveCare, Inc.'s focus on Type II diabetes?
LiveCare, Inc.'s specialized focus on Type II diabetes is significant because it targets a large and growing patient population with a critical need for ongoing disease management. Type II diabetes is a chronic condition requiring continuous monitoring and lifestyle adjustments, making it an ideal candidate for telehealth and remote patient monitoring solutions. This niche focus allows LiveCare to develop highly specialized and tailored technological advancements and support services, potentially leading to deeper expertise and more effective outcomes compared to generalized healthcare platforms. However, it also means the company's growth is tied to the dynamics of this specific disease market and its ability to differentiate its solutions within it.
What are the key factors to evaluate for LVCE?
LiveCare, Inc. (LVCE) holds an AI score of 46/100 (low). Not financial advice.
How frequently does LVCE data refresh on this page?
LVCE prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven LVCE's recent stock price performance?
LiveCare, Inc. (LVCE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on Type II diabetes, addressing a significant and growing health challenge. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial and operational data provided, especially regarding revenue, specific product details, and market penetration.
- Inferred business model details based on general industry practices for remote patient monitoring and support services.
- CEO background and track record are based on company founding date and stated mission due to lack of specific biographical data.
- Competitors section is 'Unknown' as no FMP PEER TICKERS were provided.
- Market cap of 357K is taken literally from source, implying extremely low or untracked valuation.